---
id: 175
title: Babesia microti (Babesiosis)
category: organisms
subcategory: protozoa_parasites
tags: [Babesia, babesiosis, tick-borne, Ixodes, hemolysis, atovaquone, azithromycin, clindamycin, quinine]
difficulty: medium
---

## Question

How is babesiosis diagnosed and treated? Use the **"Ixodes Tick (Northeast), Hemolytic Anemia, Maltese Cross → Atovaquone + Azithro (Mild) or Clinda + Quinine (Severe)"** framework.

## Answer

### ***Babesia microti* Overview:**

**Transmission:**
- **Ixodes scapularis tick** (same tick as Lyme, anaplasmosis, *Powassan* virus)
- **Transfusion-transmitted** (blood products, can persist for months)
- **Transplacental** (rare)

**Geography:**
- **Endemic:** Northeastern US (Massachusetts, Connecticut, Rhode Island, New York, New Jersey), Upper Midwest (Wisconsin, Minnesota)
- **Expanding range**

**Co-infection:**
- **Up to 20-40%** co-infected with *Borrelia burgdorferi* (Lyme disease) or *Anaplasma phagocytophilum*

### **Clinical Presentation:**

**Asymptomatic:**
- **25-50%** of immunocompetent (incidental finding on blood smear or serology)

**Mild-Moderate (Immunocompetent):**
- **Gradual onset** (1-4 weeks after tick bite)
- **Fever, chills, sweats** (drenching night sweats)
- **Fatigue, malaise, headache**
- **Myalgia, arthralgia**
- **Mild hemolytic anemia** (jaundice, dark urine)

**Severe (High-Risk Groups):**

**Risk Factors:**
- **Asplenia** (highest risk, fulminant infection)
- **Age >50 years**
- **Immunosuppression** (HIV, malignancy, transplant)

**Manifestations:**
- **Severe hemolytic anemia** (Hb <10 g/dL, ↑LDH, ↑indirect bilirubin, ↓haptoglobin)
- **High parasitemia** (>10%, can be >20-30% in asplenia)
- **Acute respiratory distress** (ARDS)
- **Disseminated intravascular coagulation** (DIC)
- **Renal failure** (hemoglobinuria, ATN)
- **Shock**
- **Mortality:** 5-10% overall, up to 20% in severe cases

### **Diagnosis:**

**Blood Smear (Gold Standard):**
- **Thin smear (Giemsa or Wright stain):** Intraerythrocytic parasites (ring forms, pear-shaped)
- **"Maltese cross" (tetrad):** 4 merozoites arranged in cross pattern (pathognomonic, but seen in <1% of cases)
- **Differentiating from malaria:**
  - **Babesia:** NO pigment (hemozoin), extracellular forms rare
  - **Malaria:** Pigment present, extracellular gametocytes

**PCR:**
- **Most sensitive** (especially low parasitemia)
- **Gold standard** in blood banks (screening donors)

**Serology (IFA):**
- **IgM/IgG antibodies**
- **Positive ≥1:64** (acute infection)
- **Useful for retrospective diagnosis** (not acute management)
- **Remains positive** for months to years (cannot use to monitor treatment response)

**Labs:**
- **Hemolytic anemia:** ↓Hb, ↑reticulocytes, ↑LDH, ↑indirect bilirubin, ↓haptoglobin
- **Thrombocytopenia** (common)
- **Elevated transaminases**

### **Treatment:**

**Mild-Moderate Disease (Immunocompetent):**
- **Atovaquone 750mg PO BID + azithromycin 500mg PO × 1, then 250mg daily × 7-10 days**
- **Better tolerated** than clindamycin + quinine

**Severe Disease (High Parasitemia >10%, Asplenia, Organ Dysfunction):**
- **Clindamycin 600mg IV q8h (or 600mg PO TID) + quinine 650mg PO TID × 7-10 days**
- **Switch to atovaquone + azithromycin** if improved (better tolerated for completion)

**High-Risk / Relapsing Disease:**
- **Longer duration:** ≥6 weeks (or until parasitemia cleared + symptoms resolved)
- **Asplenia, immunosuppressed:** Treat for **≥6 weeks**, monitor parasitemia weekly

**Exchange Transfusion:**
- **Consider if:**
  - **Parasitemia >10%** (especially if symptomatic)
  - **Severe hemolysis** (Hb <10 g/dL with ongoing hemolysis)
  - **Organ dysfunction** (renal failure, ARDS, altered mental status)
- **Adjunctive** (give with antimicrobials)

**Asymptomatic / Incidental Finding:**
- **Treat regardless** (risk of relapse, blood transfusion transmission)
- **Atovaquone + azithromycin × 7-10 days**

### **Prevention:**

**Tick Avoidance:**
- **Same prevention as Lyme** (protective clothing, DEET, permethrin, tick checks)

**Blood Donor Screening:**
- **PCR screening** in endemic areas (FDA-mandated)

**Post-Treatment:**
- **Defer blood donation** for 2 years after treatment (can have persistent low-level parasitemia)

## Key Points

### **Maltese Cross:**
- **Pathognomonic** (4 merozoites in cross pattern)
- **Rare (<1%)** - do NOT rely on this finding

### **Asplenia = Highest Risk:**
- **Fulminant infection** (parasitemia >10-30%, ARDS, shock)
- **High mortality** without treatment
- **Longer treatment** (≥6 weeks)

### **Atovaquone + Azithromycin = Preferred:**
- **Better tolerated** than clindamycin + quinine
- **Fewer side effects** (quinine → tinnitus, cinchonism, QT prolongation)
- **Use for mild-moderate disease**

### **Clindamycin + Quinine = Severe Disease:**
- **IV clindamycin + PO quinine** (severe cases)
- **More effective** for high parasitemia
- **Switch to atovaquone + azithromycin** once improved

### **Exchange Transfusion:**
- **Parasitemia >10%** with symptoms or organ dysfunction
- **Rapidly reduces parasite burden**
- **Adjunctive** (give with antimicrobials)

### **Co-infection Common:**
- **20-40%** co-infected with *Borrelia* (Lyme) or *Anaplasma*
- **Test for co-infections** (serology, PCR)
- **May need doxycycline** (if Lyme or anaplasmosis present)

### **Clinical Pearls:**
- **Ixodes tick** (same as Lyme), **Northeast/Upper Midwest US**
- **Hemolytic anemia** (jaundice, dark urine, ↑LDH, ↓haptoglobin)
- **Intraerythrocytic ring forms** (blood smear), "Maltese cross" pathognomonic but rare
- **Mild-moderate:** Atovaquone + azithromycin × 7-10 days
- **Severe (parasitemia >10%, asplenia, organ dysfunction):** Clindamycin + quinine ± exchange transfusion
- **Co-infection:** 20-40% with Lyme or anaplasmosis

## Sources

- [IDSA: Babesiosis Guidelines 2024]
- [CDC: Babesiosis Surveillance 2024]

## Media

N/A
